Related Experiment Video

Updated: Oct 1, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Group C meningococcal vaccine trial: safety, immunogenicity and parents' views of participation

C Jonas

    Paediatric Nursing
    |May 25, 2002
    PubMed

    Insights

    A meningococcal C conjugate vaccine was found safe and effective in infants, showing good tolerance and increased antibody levels. Parent feedback also offered valuable insights for future infant vaccination trials.

    Area of Science:

    • Pediatric Vaccinology
    • Immunology
    • Public Health

    Background:

    • Meningococcal disease poses a significant risk to infants.
    • Development of conjugate vaccines is crucial for effective prevention.
    • Infant vaccination schedules require rigorous safety and immunogenicity testing.

    Purpose of the Study:

    • To assess the safety and immunogenicity of a novel Group C meningococcal conjugate vaccine.
    • To gather parental perspectives on infant vaccination trials.
    • To inform best practices for pediatric vaccine research.

    Main Methods:

    • A cohort of 182 infants received the Group C meningococcal conjugate vaccine.
    • Safety was monitored through local and systemic reaction assessments.
    • Immunogenicity was evaluated by measuring post-vaccination antibody levels.
    • Parental feedback was collected throughout the study.

    Main Results:

    • The meningococcal C conjugate vaccine was well tolerated in infants.
    • Fewer local reactions were observed compared to routine vaccinations.
    • No increase in systemic reactions was reported.
    • Progressive increases in antibody levels were noted after each vaccine dose.

    Conclusions:

    • The evaluated meningococcal C conjugate vaccine is safe and immunogenic in infants.
    • Parental input is vital for successful pediatric clinical trials.
    • Findings provide essential data for the UK vaccination schedule and future infant vaccine research.

    More Related Videos

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

    Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

    Published on: November 5, 2019

    Related Concept Videos

    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    Bacterial Meningitis II: Pathophysiology01:26

    Bacterial Meningitis II: Pathophysiology

    Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...